You searched for lung cancer | Page 91 of 153

FDA Approves First NGS-Based CDx for RET Fusion-Positive NSCLC

Thermo Fisher Scientific’s Oncomine Dx Target Test simultaneously evaluates 23 genes clinically associated with NSCLC.

Foundation Medicine’s FoundationOne Liquid CDx is a pan-tumor liquid biopsy test for patients with solid tumors.

This is the first approval to combine two technologies—NGS and liquid biopsy—in one diagnostic in order to guide treatment decisions.

The collaborators are pursuing regulatory approval of the Guardant360 CDx as a companion diagnostic for amivantamab for the treatment of NSCLC.

Mastering tumor heterogeneity to unlock personalized medicine